Volume 11, Number 1—January 2005
Dispatch
Distribution and Characteristics of Escherichia coli Clonal Group A1
, Andrew C. Murray*†, Michael A. Kuskowski*†, Sören Schubert‡, Marie-Francoise Prère§, Bertrand Picard¶, Raul Colodner#, Raul Raz#**, and TIARAInvestigators
Table 2
Prevalence of phylogenetic groups and Escherichia coli clonal group A (CGA) according to locale and resistance phenotype
| E. coli group† | Prevalence of indicated E. coli group by locale and TMP-SMZ* phenotype, no. (column %) |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total (N = 1,102) |
United States (N = 512) |
Non–United States (N = 590) |
||||||||||
| Overall | Susceptible (n = 516) | Resistant (n = 586) | p value‡ | Overall | Susceptible (n = 250) | Resistant (n = 262) | p value‡ | Overall | Susceptible (n = 266) | Resistant (n = 324) | p value‡ | |
| ECOR A | 168 (15) | 65 (13) | 103 (18) | 0.02 | 63 (12) | 28 (11) | 35 (13) | NS | 105 (18) | 37 (14) | 68 (21) | 0.03 |
| ECOR B1 | 143 (13) | 70 (14) | 73 (12) | NS | 59 (12) | 27 (11) | 32 (12) | NS | 84 (14) | 43 (16) | 41 (13) | NS |
| ECOR B2 | 483 (44)§ | 277 (54)§ | 210 (35) | <0.001 | 213 (42) | 134 (54)§ | 79 (30)§ | <0.001 | 270 (46) | 143 (54)§ | 127 (39)§ | <0.001 |
| ECOR D | 298 (27)§ | 98 (19)§ | 200 (34) | <0.001 | 176 (34) | 60 (24)§ ¶ | 116 (44)§# | <0.001 | 122 (21) | 38 (14)§ ¶ | 84 (26)§# | 0.001 |
| CGA | 68 (6) | 9 (1.7) | 59 (10) | <0.001 | 48 (9) | 5 (2) | 43 (16) | <0.001 | 20 (3.4) | 4 (1.5) | 16 (5) | 0.02 |
*ECOR, E. coli reference
†TMP-SMZ, trimethoprim-sulfamethoxazole.
‡p values (by Fisher exact test) for comparison of susceptible and resistant isolates are shown when <0.05. NS, not significant.
§For prevalence of group B2 (versus group D) within same column; p ≤ 0.01, McNemar’s test.
¶For prevalence of group D among U.S. (vs. non-U.S.) susceptible isolates; p = 0.005 (Fisher exact test).
#For prevalence of group D among U.S. (vs. non-U.S.) resistant isolates; p < 0.001 (Fisher exact test).
1Presented at the American Society for Microbiology 103rd General Meeting, May 18–22, 2003, Washington, D.C.
2The TIARA investigators include the following: Sacared Bodison (University of Maryland, College Park, MD), Franklin R. Cockerill, III (Mayo Clinic and Mayo Medical School, Rochester, MN), Clovis Arns da Cunha (Curitiba-PR, Brazil), Peter Echeverria and Sriluck Simasathien (Armed Forces Research Institute of Medical Sciences and Phramonkutkho Army Hospital, Bangkok, Thailand), Wim Gaastra (University of Utrecht, Utrecht, The Netherlands), Lucinda M.C. Hall (St Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK), Marina Klein (McGill University Health Centre, Montreal, Quebec, Canada), Hank A. Lockman (Battelle Memorial Institute, Columbus, OH), Imad Omer and Jane R. Schwebke (University of Alabama, Birmingham, AL), Guillem Prats (Hospital Vall d'Hebron, Barcelona, Spain), Robert M. Rakita (Virginia Mason Medical Center, Seattle, WA), Susan Rossman (Texas Childrens Hospital, Houston, TX), Ronald Schiffman (Southern Arizona VA Medical Center, Tucson, AZ), Ronald Smith (Billings Clinic and Providence Medical Center, Billings, MT), and Patricia L. Winokur (VA Medical Center and University of Iowa, Iowa City, IA).